All articles by Phillip Broadwith – Page 13
-
Business
Alexion to buy Synageva for rare disease drugs
$8.4bn deal gives firm access to enzyme drug currently under review with US and EU regulators
-
Business
Takeda offers $2.4bn to settle diabetes litigation
Aims to settle multiple outstanding lawsuits relating to Actos (pioglitazone) and bladder cancer
-
Business
Zoetis to sell or close 10 plants in cost-cutting drive
Animal health firm will slash product portfolio in a bid to save $300m annually
-
BusinessKolon and Dupont settle trade secrets case
Korean firm admits stealing Kevlar technology and will pay $360m in fines and restitution
-
Business
Daiichi Sankyo steps out after Sun-Ranbaxy merger
Ranbaxy’s Japanese owner has sold off its stake in the merged company, but will retain its business partnership
-
BusinessEnvironmental research goes private
Exclusive interview with Fera chief Hilary Aldridge as the UK’s Food and Environment Research Agency becomes majority-owned by Capita
-
Business
Valeant heads off Endo bid for Salix
Bid raised to $15.8 billion in cash after rival offer from Irish firm
-
Business
BASF introduces bio-based polyTHF
Process uses 1,4-butanediol from microbial digestion of sugar feedstocks to make component of polyester and polyurethane materials
-
Business
Mallinckrodt to buy Ikaria to expand in US hospitals
$2.3bn deal brings nitric oxide ventilator system for newborns with respiratory failure
-
Business
J&J to sell cardiac devices to wholesaler Cardinal
Commodity technology no longer fits with company’s focus on growth and innovation
-
Business
AstraZeneca to spin off anti-infectives research
Early-stage research will transfer to a new company, while AZ and MedImmune retain late-stage programmes
-
Business
Asahi Kasei to buy Polypore for battery materials
$2.2bn deal adds to Japanese consolidation in energy storage
-
BusinessCatalytic carbon dioxide convertors
Company profile: Econic Technologies makes catalysts that build carbon dioxide into performance polymers
-
Business
BMS bolsters immuno-oncology with pair of deals
Firm will acquire Flexus Biosciences and collaborate with Rigel
-
Business
Europe approves stem cell therapy
Treatment for burn-damaged eyes uses patient’s own scaffold-grown cells
-
Business
Valeant to buy Salix for $14.5bn
Companies expect $500m in savings through ‘R&D rationalisation’
-
-
Business
Teva wins generic esomeprazole race
US approval of heartburn drug after Ranbaxy version was withdrawn by regulators